US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
Executive Summary
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
You may also be interested in...
Consumer Health Care Roundup: DXM Abuse Rate Stays Steady; OTC Device Claim Fails
DXM abuse rate is up for 8th graders but down for older teens in a US federally sponsored survey; UK agency finds BioEnergiser doesn't support ad claims for OTC Sciaticure Acupressure Wrap.
Consumer Health Care Roundup: DXM Abuse Rate Stays Steady; OTC Device Claim Fails
DXM abuse rate is up for 8th graders but down for older teens in a US federally sponsored survey; UK agency finds BioEnergiser doesn't support ad claims for OTC Sciaticure Acupressure Wrap.
OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House
With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.